1. Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP and Trent JM (1987) Pharmacological, molecular, and cytogenetic analysis of ?atypical? multidrug-resistant human leukemia cells. Cancer. Res. 47: 5455?5460.
2. Beck WT and Danks MK (1991a) Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Semin. Cancer Biol. 2: 235?244.
3. Beck WT and Danks MK (1991b) Multidrug resistance associated with alterations in topoisomerase II. In: Potmesil M and Kohn K (eds) DNA Topoisomerases in Cancer (pp. 260?275) Oxford University Press, New York.
4. Beck WT, Danks MK and Wolverton JS (1993) Distribution of topoisomerase II and its response to VM-26 in drug-sensitive and-resistant human leukemic cells. In: Andoh T, Ikeda H and Oguro M (eds) Molecular Biology of DNA Topoisomerases and its Application to Chemotherapy (pp. 275?285) CRC Press, Boca Raton, Florida.
5. Bugg BY, Danks MK, Beck WT and Suttle DP (1991) Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc. Natl. Acad. Sci. USA 88: 7654?7658.